目的 探討貞芪益腎顆粒聯(lián)合來氟米特片治療慢性腎小球腎炎的臨床療效。方法 選取2019年3月-2020年9月在漯河市中心醫(yī)院就診的110例慢性腎小球腎炎患者作為本研究對象，將全部患者按照隨機(jī)數(shù)字表法分為對照組和治療組，每組各55例。對照組口服來氟米特片，20 mg/次，1次/d。治療組在對照組基礎(chǔ)上溫水沖服貞芪益腎顆粒，9 g/次，1次/d。兩組患者連續(xù)治療8周。觀察兩組的療效，比較兩組的腎功能指標(biāo)和血清炎性因子指標(biāo)。結(jié)果 治療后，治療組的總有效率為92.75%，對照組的總有效率為78.18%，組間差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組的肌酐（Scr）、尿素氮（BUN）、胱抑素C（Cys-C）、24 h尿蛋白定量水平均顯著降低，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組腎功能指標(biāo)降低的更明顯，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組的超敏C反應(yīng)蛋白（hs-CRP）、白細(xì)胞介素-1β（IL-1β）、單核細(xì)胞趨化蛋白-1（MCP-1）、白細(xì)胞介素-17（IL-17）水平均明顯降低（P<0.05）；治療后，治療組的hs-CRP、IL-1β、MCP-1、IL-17水平低于對照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 貞芪益腎顆粒聯(lián)合來氟米特片可提高慢性腎小球腎炎的療效，進(jìn)一步減輕炎癥反應(yīng)，改善腎功能，且安全性良好。

Objective To investigate the clinical effect of Zhenqiyishen Granules combined with Leflunomide Tablets in treatment of chronic glomerulonephritis. Methods Patients (110 cases) with chronic glomerulonephritis in Luohe Central Hospital from March 2019 to September 2015 were randomly divided into control and treatment groups, and each group had 55 cases. Patients in the control group were po administered with Leflunomide Tablets, 20 mg/time, once daily. Patients in the treatment group were po administered with Zhenqiyishen Granules on the basis of the control group, 9 g/time, once daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacies were evaluated, and renal function index and serum inflammatory factor factors in two groups were compared. Results After treatment, the total effective rates were 92.75% and 78.18% in the treatment group and control group, and the difference was statistically significant (P<0.05). After treatment, the levels of SCR, BUN, Cys-C, and 24 h urinary protein in two groups were significantly decreased, and the difference was statistically significant (P<0.05). And these indexes in the treatment group were significantly lower than those in the control group, and the difference was statistically significant (P<0.05). After treatment, the levels of hs-CRP, IL-1β, MCP-1, and IL-17 in two groups were significantly decreased (P<0.05). After treatment, the levels of hs-CRP, IL-1β, MCP-1, and IL-17 in the treatment group were lower than those in the control group, and the difference was statistically significant (P<0.05). Conclusion Zhenqiyishen Granules combined with Leflunomide Tablets can improve the curative effect of chronic glomerulonephritis, further reduce inflammatory reaction, and improve renal function, with good safety.

R983

河南省中醫(yī)藥科學(xué)研究專項(xiàng)課題（2018ZY2030）